Collaborative Arrangement, Notice of Termination, Effective Period from Notice

No definition available.

Name:	irwd_CollaborativeArrangementNoticeOfTerminationEffectivePeriodFromNotice
Namespace Prefix:	irwd_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of loss on inventory and purchase commitments due to revised demand forecasts.

+ References

No definition available.

+ Details

Name:	irwd_InventoryAndPurchaseCommitmentsWriteDown
Namespace Prefix:	irwd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Inventory Write-down of Net Realizable Value, and Loss on Non-cancellable Purchase Commitments

+ References

No definition available.

+ Details

Name:	irwd_InventoryWriteDownOfNetRealizableValueAndLossOnNonCancellablePurchaseCommitments
Namespace Prefix:	irwd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275

+ Details

Name:	us-gaap_ImpairmentOfIntangibleAssetsFinitelived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=irwd_AstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Subsequent Events - Lesinurad License Agreement Termination - Reduced Projected Revenue and Net Cash Flow Assumptions (Details) - USD ($) $ in Thousands		3 Months Ended			6 Months Ended
	Aug. 02, 2018	Sep. 30, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Subsequent Events
Impairment of finite-lived intangible					$ 0
Non-cash change in fair value of contingent consideration			$ 1,962	$ 6,933	2,474	$ 8,547
Inventory and purchase commitments write down					2,200
Write-down of commercial supply and inventory to net realizable value and loss on non-cancellable purchase commitments			$ 1,836	$ 96	1,836	$ 96
Selling, general and administrative
Subsequent Events
Inventory and purchase commitments write down					$ 400
Subsequent Event \| Forecast
Subsequent Events
Impairment of finite-lived intangible		$ 150,000
Non-cash change in fair value of contingent consideration		$ (30,000)
Subsequent Event \| Licensing agreement \| AstraZeneca
Subsequent Events
Effective period from notice	180 days